Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-hLL2 Radioimmunotherapy in Non-Hodgkin's Lymphoma
NCT00421395Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2002
- Primary completion
- Oct 2007
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
A Phase 2 trial of 90Y-epratuzumab tetraxetan in Non-Hodgkin lymphoma (NHL), sponsored by Gilead Sciences. Started Aug 2002; status: completed.
02
Drugs
90Y-epratuzumab tetraxetan
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00421395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421395.